BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 3,398 shares of BeiGene stock in a transaction dated Monday, June 7th. The stock was sold at an average price of $352.54, for a total value of $1,197,930.92. Following the sale, the chief operating officer now directly owns 1,150,757 shares in the company, valued at $405,687,872.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Xiaobin Wu also recently made the following trade(s):
- On Monday, May 3rd, Xiaobin Wu sold 6,715 shares of BeiGene stock. The stock was sold at an average price of $343.00, for a total value of $2,303,245.00.
Shares of BeiGene stock opened at $346.91 on Friday. BeiGene, Ltd. has a fifty-two week low of $155.16 and a fifty-two week high of $388.97. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.62 and a quick ratio of 4.56. The firm has a market capitalization of $31.85 billion, a price-to-earnings ratio of -25.45 and a beta of 0.87. The company has a 50 day moving average of $328.80.
BeiGene (NASDAQ:BGNE) last issued its earnings results on Friday, May 7th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.90) by $2.59. BeiGene had a negative net margin of 135.24% and a negative return on equity of 31.71%. Research analysts expect that BeiGene, Ltd. will post -11.88 earnings per share for the current year.
Several research analysts recently weighed in on the stock. Cowen boosted their price objective on shares of BeiGene from $348.00 to $429.00 and gave the stock an “outperform” rating in a research report on Thursday, February 18th. Zacks Investment Research upgraded shares of BeiGene from a “sell” rating to a “hold” rating in a research note on Tuesday, May 11th. Morgan Stanley increased their price objective on shares of BeiGene from $357.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, June 3rd. China Renaissance Securities initiated coverage on shares of BeiGene in a report on Monday, March 8th. They issued a “buy” rating on the stock. Finally, HSBC increased their price target on shares of BeiGene from $296.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, March 16th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $322.33.
A number of institutional investors have recently modified their holdings of BGNE. Marshall Wace North America L.P. acquired a new stake in BeiGene in the first quarter valued at approximately $76,000. Amundi Pioneer Asset Management Inc. boosted its position in BeiGene by 9.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 17,001 shares of the company’s stock valued at $2,244,000 after buying an additional 1,500 shares in the last quarter. NN Investment Partners Holdings N.V. boosted its position in BeiGene by 67.6% in the fourth quarter. NN Investment Partners Holdings N.V. now owns 11,400 shares of the company’s stock valued at $2,945,000 after buying an additional 4,600 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of BeiGene by 35.0% during the fourth quarter. Parallel Advisors LLC now owns 135 shares of the company’s stock worth $35,000 after purchasing an additional 35 shares during the period. Finally, First Trust Advisors LP lifted its holdings in shares of BeiGene by 16.1% during the fourth quarter. First Trust Advisors LP now owns 6,386 shares of the company’s stock worth $1,650,000 after purchasing an additional 887 shares during the period. Hedge funds and other institutional investors own 61.50% of the company’s stock.
BeiGene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
Featured Article: Why are analyst ratings important in trading stocks?